Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

Increased investment by the pharmaceutical and biotechnology majors in offshore early drug development creates opportunities and challenges for outsourcing.

Globalizing Drug Development

Congress is considering proposing a new chemical policy similar to the European Union’s REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) regulation. Batch and custom manufacturers weigh in on the debate.

Will REACH Reach the US?

Congressional hearings were held last week on the Food and Drug Administration Globalization Act discussion draft.

Congress, FDA Weigh in on Measures to Improve Drug Safety

Also, FDA removes OAI status for Watson's Florida facility, executive management changes as GSK, more...

Company and People Notes: Actavis Totowa Recalls "Digitek," Cynthia Schwalm Named President of Eisai Inc., More

Michelle Hoffman, editorial director of Pharmaceutical Technology.

Scientists are giving up on a preventive vaccine for AIDS, but there are lessons to be learned.

Requiem for a Vaccine

Florida is making its case for pharmaceutical and biotechnology research and development.

Florida Builds its Position in the Life Sciences

Irwin Silverstein, PhD, is vice-president and chief operating officer at International Pharmaceutical Excipients Auditing, 1655 N. Fort Myer Drive, Suite 700, Arlington, VA 22209, tel. 703.351.5266.

The less complex nature of excipient manufacturers, as compared with API manufactures, carries many benefits.

Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart

Chemocatalytic and biocatalytic routes show promise for more efficient syntheses of select active ingredients.

Unfolding Catalytic Routes to APIs

The pharmaceutical industry must address the release of nonbiodegradable APIs into the environment.

Tackling waste water with nanofiltration membranes

Congress is taking on the issue of inspection of foreign drug-manufacturing facilities as it began hearings on a discussion draft of the Food and Drug Administration Act of 2008.

Ingredients